Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1-specific CD8+ T cells.
Frances E PearsonKirsteen M TullettIngrid M Leal-RojasOscar L HaighKelly-Anne MastermanCarina WalpoleJohn S BridgemanJames E McLarenKristin LadellKelly MinersSian Llewellyn-LaceyDavid A PriceAntje TungerMarc SchmitzJohn J MilesMireille H LahoudKristen J RadfordPublished in: Clinical & translational immunology (2020)
Delivery of WT1 to CD141+ DCs via CLEC9A stimulates CD8+ T cells more potently than either untargeted delivery or widespread delivery to all Ag-presenting cells via DEC-205, suggesting that cross-presentation by CD141+ DCs is sufficient for effective CD8+ T-cell priming in humans. The CLEC9A-WT1 vaccine is a promising candidate immunotherapy for malignancies that express WT1.
Keyphrases
- dendritic cells
- endothelial cells
- induced apoptosis
- nk cells
- immune response
- case report
- cell cycle arrest
- regulatory t cells
- induced pluripotent stem cells
- cell proliferation
- oxidative stress
- highly efficient
- liquid chromatography
- cell death
- gas chromatography mass spectrometry
- tandem mass spectrometry
- simultaneous determination
- visible light